-
公开(公告)号：US10738289B2
公开(公告)日：2020-08-11
申请号：US15466714
申请日：2017-03-22
Applicant: CELLECTIS S.A.
Inventor： George Silva , Marine Beurdeley
Abstract: The present invention relates to a method to cleave target nucleic acid sequence by the catalytic domain of a GIY-YIG homing endonucleases I-TevI. More precisely, the invention relates to the deciphering of new preferential I-TevI cleavage sites for efficient and specific cleavage activity. The invention concerns a method for the generation of TevI specific chimeric endonucleases to target nucleic acid sequence including such cleavage sites and methods of using same for gene editing.
-
12.发明公开公开(公告)号：US20240197880A1
公开(公告)日：2024-06-20
申请号：US18556957
申请日：2022-04-29
Applicant: CELLECTIS S.A.
Inventor： Beatriz ARANDA-ORGILLES , Tomasz KURCON , Laurent POIROT
IPC: A61K39/00 , A61P35/00 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/90
CPC classification number: A61K39/46447 , A61K39/4611 , A61K39/4613 , A61K39/4631 , A61P35/00 , C07K14/7051 , C07K16/3092 , C12N5/0636 , C12N15/907 , C07K2317/622 , C07K2319/03 , C07K2319/30 , C12N2501/2302
Abstract: The present invention relates to genetically engineered immune cells expressing new anti-MUC1 chimeric antigen receptors and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
-
公开(公告)号：US20230248825A1
公开(公告)日：2023-08-10
申请号：US18005284
申请日：2021-07-23
Applicant: CELLECTIS S.A.
Inventor： Shipra DAS , Sumin JO , Alexandre JUILLERAT , Julien VALTON , Laurent POIROT , Philippe DUCHATEAU
IPC: A61K39/00 , C12N9/22 , C12N15/11 , C12N15/90 , C12N5/0783 , C12N15/113 , A61K39/395 , A61P35/00
CPC classification number: A61K39/4633 , C12N9/22 , C12N15/11 , C12N15/907 , C12N5/0636 , A61K39/4611 , A61K39/4643 , C12N15/1138 , A61K39/3955 , A61K39/4631 , A61P35/00 , C12N2800/80 , C12N2310/20 , C12N2506/11 , C12N2501/515 , C12N2501/51 , C12N2501/2302 , A61K2039/5158 , C12N2310/531 , C12N2310/14
Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.
-
14.发明授权公开(公告)号：US10301614B2
公开(公告)日：2019-05-28
申请号：US14387162
申请日：2013-03-15
Applicant: CELLECTIS, S.A.
Inventor： Philippe Duchateau , Julien Valton
Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.
-
公开(公告)号：US20170260513A1
公开(公告)日：2017-09-14
申请号：US15466714
申请日：2017-03-22
Applicant: CELLECTIS S.A.
Inventor： George Silva , Marine Beurdeley
IPC: C12N9/22 , C07K14/195 , C12N15/82 , C12N15/90
Abstract: The present invention relates to a method to cleave target nucleic acid sequence by the catalytic domain of a GIY-YIG homing endonucleases I-TevI. More precisely, the invention relates to the deciphering of new preferential I-TevI cleavage sites for efficient and specific cleavage activity. The invention concerns a method for the generation of TevI specific chimeric endonucleases to target nucleic acid sequence including such cleavage sites and methods of using same for gene editing.
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20160298098A1
公开(公告)日：2016-10-13
申请号：US15069672
申请日：2016-03-14
Applicant: CELLECTIS, S.A.
Inventor： Philippe Duchateau , Julien Valton , Claudia Bertonati , Jean-Charles Epinat , George H. Silva , Alexandre Juillerat , Marine Beurdeley
CPC classification number: C12N9/16 , A61K38/00 , C07K14/4703 , C07K2319/00 , C07K2319/80 , C12N9/22 , C12P19/34
Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a singe polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA tar et sequence of interest and process DNA nearby said DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.
Abstract translation: 本发明涉及能够有效靶向和加工双链DNA的致密转录激活子样效应核酸酶（TALENS）的生成方法。 更具体地，本发明涉及一种用于产生TALEN的方法，其由与至少一个催化结构域融合的单个TALE DNA结合结构域组成，使得活性实体由简单且有效的载体化的单个多肽链组成，并且不 需要二聚化来靶向目标特定的单链双链DNA焦油和序列，并在DNA附近处理DNA靶序列。 本发明还涉及用于实施该方法的紧凑型TALEN，载体，组合物和试剂盒。
-
17.发明公开公开(公告)号：US20240299453A1
公开(公告)日：2024-09-12
申请号：US18562536
申请日：2022-05-20
Applicant: CELLECTIS S.A. , ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
Inventor： Toni Cathomen , Tatjana Cornu , Viviane Dettmer-Monaco , Simone Haas , Julia Rositzka , Philippe Duchateau , Alexandre Juillerat
CPC classification number: A61K35/17 , A61K48/005 , C12N5/0636 , C12N9/22 , C12N15/86 , C12N15/907 , C12N2501/2302 , C12N2501/51 , C12N2501/515 , C12N2501/53 , C12N2510/00 , C12N2750/14143 , C12N2800/80 , C12N2830/42
Abstract: The present invention generally relates to the field of genome engineering (gene editing), and more specifically to gene therapy for the treatment of Hyper-lgE syndrome (HIES). In particular, the present invention provides means and methods for genetically modifying HSCs or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), thereby allowing the restoration of the normal cellular phenotype. The present invention also provides populations of engineered HSCs or T-cells which comprise cells comprising an exogenous polynucleotide sequence comprising at least a partial or complete sequence of a functional STATS gene, said exogenous polynucleotide sequence being integrated in an endogenous STATS gene comprising at least one mutation causing Hyper-lgE syndrome (HIES), resulting in the expression of a functional STATS polypeptide. The present invention further provides pharmaceutical compositions comprising the cell populations of the invention, and their use in gene therapy for the treatment of Hyper-lgE syndrome (HIES).
-
公开(公告)号：US20230279440A1
公开(公告)日：2023-09-07
申请号：US17996701
申请日：2021-05-06
Applicant: CELLECTIS S.A.
Inventor： Alexandre JUILLERAT , Philippe DUCHATEAU , Patrick HONG , Laurent POIROT , Brian BUSSER , Alex BOYNE
CPC classification number: C12N15/907 , C12N15/86 , C12N2750/14143 , C12N2830/42
Abstract: The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.
-
公开(公告)号：US20230279350A1
公开(公告)日：2023-09-07
申请号：US18016972
申请日：2021-07-30
Applicant: CELLECTIS S.A.
Inventor： André CHOULIKA , Laurent POIROT , Beatriz ARANDA ORGILLES , Philippe DUCHATEAU
IPC: C12N5/0783 , C07K16/28 , A61P35/00
CPC classification number: C12N5/0636 , C07K16/2887 , C07K16/2896 , A61P35/00 , C07K2317/53 , C07K2317/565 , C07K2319/03
Abstract: The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.
-
公开(公告)号：US20150067900A1
公开(公告)日：2015-03-05
申请号：US14384957
申请日：2013-03-15
Applicant: CELLECTIS, S.A.
Inventor： Philippe Duchateau , Alexandre Juillerat , Claudia Bertonati
IPC: A01K67/027 , C12N15/82 , C12N15/10
CPC classification number: A01K67/0275 , C12N15/10 , C12N15/63 , C12N15/82 , C12N15/8213 , C12Q1/6834 , C12Q2522/101
Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. The present invention also concerns methods to use these proteins. The present invention also relates to vectors, compositions and kits in which RVD domains and Transcription Activator-Like Effector (TALE) proteins of the present invention are used.
Abstract translation: 本发明涉及多肽，更具体地涉及允许有效靶向和/或加工核酸的转录激活子样效应物衍生蛋白。 本发明还涉及使用这些蛋白质的方法。 本发明还涉及使用本发明的RVD结构域和转录激活子效应（TALE）蛋白质的载体，组合物和试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.021 seconds)
